SE 0 9 2002 US

Docket No Hort-15 9 334

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: PAGET et al.

Serial No. : 10/072,534

Art Unit: 1614

Filed

: February 6, 2002

Examiner: N/A

For

PYRIDOARYLPHENYL OXAZOLIDINONE ANTIBACTERIALS,

AND RELATED COMPOSITIONS AND METHODS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

September 6, 2002

Joseph S. Kentoffio (Name of applicant, assignee, or Registered Representative)

September 6, 2002

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In ac	ccordance with §1.129(a), this Information
Disclosure Stat	ement is being filed in connection with \square the
first or □seco	nd After Final Submission, therefore:
	Statement in Accordance with §1.97(e) (attached);
	or
	Please charge Deposit Account No. 10-0750/ /
	the fee of $$180.00$ as set forth in $$1.17(p)$.

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $$1.17(p)$.
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in § 1.17(p).
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
There are no listed references which are not in the
English language.

 \boxtimes The relevance of those listed references which are not in the English language is as follows: for EP 0520277 A2 see corresponding issued US Patent Nos. 5,312,823 and 5,371,090. Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1579/JSK. This form is submitted in triplicate. Respectfully submitted, Røg. No. 33,189 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3711 September 6, 2002 DATED: Customer No. 000027777



RECEIVED

SEP 1 0 2002 PTO/SB/08A (08-00)

Approved for use through 1/4/1/2027A049-0551-0
U.S. Petent and Trademark Office: U.S. DEPARTIMENT OF COMMITE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	a valid OMB control number.U/29111
Application Number	10/072,534
Filing Date	02/06/2002
First Named Inventor	PAGET et al.
Group Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	ORT-1579

U.S. PATENT DOCUMENTS

	Cite No.1	U.S. Patent Docu	iment			
Examiner Initials		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		5,037,834		Brighty et al.	08/06/1991	
		5,312,823	Α	Petersen et al.	05/17/1994	
		5,371,090	Α	Petersen et al.	12/06/1994	
		5,792,765	Α	Riedl et al.	08/11/1998	
		5,910,504	А	Hutchinson	06/08/1999	
						

FOREIGN PATENT DOCUMENTS

	Cite No.1	Foreign Patent Document		nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office ³	Number ⁴ Kir	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		EP	0520277	A2	Bayer AG	06/15/1992		
		wo	93/09103	A1	The Upjohn Company	05/13/1993		
		wo	95/07271	A1	The Upjohn Company	03/16/1995		
		wo	95/25106	A1	The Upjohn Company	09/21/1995		
		wo	96/13502	A1	The Upjohn Company	05/09/1996		
		wo	98/54161	A1	Pharmacia & Upjohn Company	12/03/1998		
		wo	99/64416	A2	Zeneca Limited	12/16/1999		


Examiner	Date	
Signature	Considere	<u> </u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

SFD PTOTSE/08A (08:00) 002

Approved for use through 10/31/2002. OMB 0651-0034 002

U.S. Patent and Trademark Office: U.S. OFFIR MARTINE COMMERCE to a collection of information unbook it discharged the collection of information unbook it discharged to the collection of the collecti

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a valid QMB Admin Trumbes				
Application Number	10/072,5341 1000/2900			
Filing Date	02/06/2002			
First Named Inventor	PAGET et al.			
Group Art Unit	1614			
Examiner Name	N/A			
Attorney Docket Number	ORT-1579			

	*	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		IYER, S. et al.; "Regiospecific Synthesis of 2-Methoxy-3-methyl-1,4-benzoquinones from Maleoylcobalt Complexes and Alkynes via Lewis Acid Catalysis. A Highly Convergent Route to Isoquinoline Quinones." J. Am. Chem. Soc. 1987, 109, pp. 2759-2770.	
		KAMAL, M.R. et al.; "The Chemistry of Pyrazine and Its Derivatives. VII. The Synthesis of Vinylpyrazine and Substituted Vinylpyrazines." The J. of Org. Chem, 1962, Vol. 27, pp. 1363-1366.	-
		PIERA, F. et al.; "Synthesis of Substituted Pyrazines Derived From Pyrazincarboxaldehyde and Hydroxmethylpyrazine." Anales de Quimica, 1979, Vol. 75, pp. 899-903.	
		SAHU, D.P.; "A practical synthesis of 7-ethyl-octahydro-2-methyl-6H-pyrazino-[1,2-c]pyrimidin-6-one(Centperazine), an anti-filarial drug." Indian J. of Chem., Sec. B, 1998, 37, pp. 1149-1152.	
,	ł		

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.